This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
26 Oct 2011

LIVE FROM CPHI Worldwide: Alliance to Manufacture Codeine for UK Market

Aesica and Noramco have formed a partnership that has involved a technical transfer of a process for the manufacture of codeine phosphate from a unique, patented poppy supplied by Noramco’s sister company, Tasmanian Alkaloids, allowing for the conversion of the extracted alkaloid to a finished API in a one-step process for codeine phosphate.

Pharmaceutical manufacturer, Aesica, has announced the formation of a manufacturing relationship with Noramco to provide the UK market with an alternative source of controlled drugs.

 

Aesica and Noramco have formed an integrated value chain comprising raw material supply security, technical excellence, production facilities, and regulatory expertise.

 

The alliance has involved a technical transfer of a process for the manufacture of codeine phosphate from a unique, patented poppy supplied by Noramco’s sister company, Tasmanian Alkaloids, allowing for the conversion of the extracted alkaloid to a finished API in a one-step process for codeine phosphate. This has led to a reduction in the environmental impact of the production of the Active Pharmaceutical Ingredient

Related News